Maria Joosten

Maria Joosten

Auto-generated profile, based on publicly available information

Maria Joosten

Charité - Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke Alina. Zoern
Wiebke Alina. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Objective: The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often results in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate.This study aimed to identify molecular profiles associated with long-term/short-term survival in HGSC, with the goal of better understanding protective factors and developing new treatments. Experimental Design: To discover molecular drivers causing aggressiveness of HGSC, tumor samples from 12 long-term HGSC survivors (> 7 years overall survival) and 12 short-term survivors (< 1 year overall survival) were analyzed using targeted RNA sequencing followed by computational analysis. We investigated differentially expressed genes and their functional relevance, inferred differences in cell-type composition and signaling pathways as well as mutation status. To validate our findings, we simulated our study design by using HGSC TCGA dataset samples. We evaluated differential patterns of gene expression between these two groups and developed molecular profiles of HGSC that correlate with survival phenotypes. Results: Besides known molecular cancer drivers and indicators of poor prognosis, we identified specific transcriptional changes between short-term and long-term survivors of HGSC which indicate that immune processes play a fundamental role in long-term survivors. Our computational analysis reveals an important role of the ensemble of IFN-γ signaling and the RFX transcription factors as well as the immune cell composition of the tumor microenvironment. Conclusion: Specific immunologic requirements involving IFN-γ signaling and affected pathways seem to be relevant for long term survival in the generally considered non-immunogenic HGSC, requesting further research to improve diagnostic strategies and targeted therapies.

15 September 2025
Verified
Other
Open access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke A. Zoern
Wiebke A. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Figure S4 shows the results of the DEG Analysis in the TCGA cohort A. DEGs in the TCGA (red = up in STS, blue = up in LTS) cohort B. Volcano plot

15 September 2025
Verified
Other
Open access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke A. Zoern
Wiebke A. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.

15 September 2025
Verified
Other
Open access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke A. Zoern
Wiebke A. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.

15 September 2025
Verified
Other
Open access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke A. Zoern
Wiebke A. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Figure S6 presents Boxplots showing differences in BRCA1/2, KRAS, RB1, CCNE1 expression between LTS and STS in the Charité cohort.

15 September 2025
Verified
Other
Open access
SMSofya Marchenko
Sofya Marchenko
NGNiklas Goernitz
Niklas Goernitz
WZWiebke A. Zoern
Wiebke A. Zoern
MJMaria Joosten
Maria Joosten
IHInga Hoffmann
Inga Hoffmann
ETEliane Tabea Taube
Eliane Tabea Taube
Table S4 displays the characteristics and subtypes of the Charité cohort.